Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.31 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24848326 | 1.00 | HRH3 (0.37) | HRH3CYP2D6KCNH2VCPTP53 | |
| SCHEMBL14453903 | 1.00 | HRH3 (0.37) | HRH3CYP2D6KCNH2VCPTP53 | |
| SCHEMBL20906889 | 0.93 | HRH3 (0.35) | HRH3CYP2D6KCNH2TSHR | |
| SCHEMBL14453902 | 0.89 | HRH3 (0.41) | HRH3CYP2D6KCNH2VCPTP53 | |
| SCHEMBL8259210 | 0.88 | HRH3 (0.34) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL21077359 | 0.88 | HRH3 (0.34) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL14453887 | 0.88 | HRH3 (0.39) | HRH3CYP2D6TSHR | |
| SCHEMBL19105490 | 0.87 | L3MBTL3 (0.42) | HRH3L3MBTL3MBTD1L3MBTL1 | |
| SCHEMBL24854010 | 0.87 | L3MBTL3 (0.38) | HRH3L3MBTL3MBTD1L3MBTL1 | |
| SCHEMBL19699827 | 0.87 | L3MBTL3 (0.38) | HRH3L3MBTL3MBTD1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | HRH3 3763/4885CYP2D6 474/4885KCNH2 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.